Abstract:DC-SIGN (CD209) and L-SIGN (CD209L) are two C-type lectin receptors (CLRs) that facilitate SARS-CoV-2 infections as viral co-receptors. SARS-CoV-2 manipulates both DC-SIGN and L-SIGN for enhanced infection, leading to interest in developing receptor antagonists. Despite their structural similarity (82% sequence identity), they function differently. DC-SIGN, found in dendritic cells, shapes the immune response by recognizing pathogen-associated carbohydrate patterns. In contrast, L-SIGN, expressed in airway epithelial endothelial cells, is not directly involved in immunity. COVID-19’s primary threat is the hyperactivation of the immune system, potentially reinforced if DC-SIGN engages with exogenous ligands. Therefore, L-SIGN, co-localized with ACE2-expressing cells in the respiratory tract, is a more suitable target for anti-adhesion therapy. However, designing a selective ligand for L-SIGN is challenging due to the high sequence identity of the Carbohydrate Recognition Domains (CRDs) of the two lectins. We here present Man84, a mannose ring modified with a methylene guanidine triazole at position 2. It binds L-SIGN with a KD of 12.7 μM ± 1 μM (ITC) and is the first known L-SIGN selective ligand, showing 50-fold selectivity over DC-SIGN (SPR). The X-ray structure of the L-SIGN CRD/Man84 complex reveals the guanidinium group’s role in achieving steric and electrostatic complementarity with L-SIGN. This allows us to trace the source of selectivity to a single amino acid difference between the two CRDs. NMR analysis confirms the binding mode in solution, highlighting Man84’s conformational selection upon complex formation. Dimeric versions of Man84 achieve additional selectivity and avidity in the low nanomolar range. These compounds selectively inhibit L-SIGN dependent trans-infection by SARS-CoV-2 and Ebola virus. Man84 and its dimeric constructs display the best affinity and avidity reported to date for low-valency glycomimetics targeting CLRs. They are promising tools for competing with SARS-CoV-2 anchoring in the respiratory tract and have potential for other medical applications.

DC‐SIGN : un récepteur viral à large spectre

Role of DC-SIGN Induced Signaling Pathway in the Activation of HIV-1 Virus

The role of DC-SIGN as a trans-receptor in infection by MERS-CoV

When Dendritic Cells Go Viral: The Role of Siglec-1 in Host Defense and Dissemination of Enveloped Viruses

Molecular recognition of Escherichia coli R1-type core lipooligosaccharide by DC-SIGN

DC-SIGN and L-SIGN Are High Affinity Binding Receptors for Hepatitis C Virus Glycoprotein E2*

DC-SIGN Is the Major Mycobacterium tuberculosis Receptor on Human Dendritic Cells

Identification of Important N-Linked Glycosylation Sites in the Hemagglutinin Protein and Their Functional Impact on DC-SIGN Mediated Avian Influenza H5N1 Infection

The Molecule of DC-SIGN Captures Enterovirus 71 and Confers Dendritic Cell-Mediated Viral Trans-Infection

Probing the pH-dependency of DC-SIGN/R multivalent lectin-glycan interactions using polyvalent glycan-gold nanoparticles

Synthesis of a series of novel homo-and hetero-glycoclusters and their binding activities to DC-SIGN

Dissecting Multivalent Lectin–Carbohydrate Recognition Using Polyvalent Multifunctional Glycan-Quantum Dots

Unprecedented selectivity for homologous lectin targets: differential targeting of the viral receptors L-SIGN and DC-SIGN

Probing the pH-dependency of DC-SIGN/R based multivalent lectin-glycan interactions using polyvalent glycan-gold nanoparticles

Le Semliki Forest Virus, Vecteur D’expression De Gènes Dans Les Neurones in Vivo : Application À La Détection De La Glycoprotéine D’enveloppe Du VIH in Situ Dans Le Cerveau De Rat

Selection of DNA Aptamers Against DC-SIGN Protein

DC-SIGN and immunoregulation.

Dendritic-cell-specific ICAM3-grabbing Non-Integrin is Essential for the Productive Infection of Human Dendritic Cells by Mosquito-Cell-derived Dengue Viruses.

DC-SIGN Increases Japanese Encephalitis Virus Infection

Combating DC-SIGN-mediated SARS-CoV-2 dissemination by glycan-mimicking polymers